Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection.
OBJECTIVE:The study aimed to evaluate the prevalence and predictor factors for compensated advanced chronic liver disease (c-ACLD) in patients with hepatitis Delta virus (HDV) infection. METHODS:This cross-sectional study included consecutive HDV-infected patients defined by positive anti-HDV. Patie...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5362235?pdf=render |
| _version_ | 1818972924384641024 |
|---|---|
| author | Ingrid Couto Marilu Victoria Valdiléa G Veloso Lorena Rodrigues Beatriz Grinsztejn Marcus Lacerda Flamir Victoria Hugo Perazzo |
| author_facet | Ingrid Couto Marilu Victoria Valdiléa G Veloso Lorena Rodrigues Beatriz Grinsztejn Marcus Lacerda Flamir Victoria Hugo Perazzo |
| author_sort | Ingrid Couto |
| collection | DOAJ |
| description | OBJECTIVE:The study aimed to evaluate the prevalence and predictor factors for compensated advanced chronic liver disease (c-ACLD) in patients with hepatitis Delta virus (HDV) infection. METHODS:This cross-sectional study included consecutive HDV-infected patients defined by positive anti-HDV. Patients with hepatitis C coinfection, liver transplantation or presence of conditions that limit liver (LSM) or spleen stiffness measurement (SSM) were excluded. Blood tests, abdominal ultrasound, SSM and LSM by transient elastography (FibroScan®) were performed at the same day. Alcohol consumption was quantified using the AUDIT score and c-ACLD was defined by LSM ≥ 15 kPa performed by an experimented operator blinded for clinical and laboratory data. RESULTS:101 patients were eligible and few patients were excluded due to negative anti-HDV (n = 7), hepatitis C coinfection (n = 2), liver transplantation (n = 10) and limitation for LSM or SSM (n = 5). Therefore, 77 patients [61% male, age = 43 (IQR,36-52) years] were included. The prevalence of c-ACLD was 57% (n = 44/77). Patients with c-ACLD had a higher rate of detectable HBV viral load (p = 0.039), higher levels of transaminases, GGT, alkaline phosphatases, total bilirubin and INR (p<0.001 for all), as well as lower platelet count and albumin levels (p>0.001 for both) compared to those without c-ACLD. Patients with c-ACLD had higher SSM [65.2 (IQR,33.8-75.0) vs 21.8 (16.5-32.0) kPa; p<0.001] and higher splenic volume [475 (IQR,311-746) vs 154 (112-283) cm3; p<0.001] compared to those without. Detectable HBV viral load (>10 UI/ml), alkaline phosphatase (per IU/L) and GGT levels (per IU/L) were independently associated with c-ACLD in all multivariate models. Splenic volume [per cm3,OR = 1.01 (95%CI,1.01-1.02);p = 0.002], SSM [per kPa, OR = 1.04 (1.01-1.07);p = 0.012] and splenomegaly [yes vs no,OR = 28.45 (4.42-182.95);p<0.001] were independently associated with c-ACLD. CONCLUSIONS:The prevalence of c-ACLD was high in patients with chronic HDV infection in western Amazon basin. HBV viral load, liver enzymes and splenic features can be used to predict severe liver disease in HDV-infected patients. |
| first_indexed | 2024-12-20T15:16:00Z |
| format | Article |
| id | doaj.art-e3476f47017b43a2bd47ee82d82b1c34 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T15:16:00Z |
| publishDate | 2017-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e3476f47017b43a2bd47ee82d82b1c342022-12-21T19:36:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01123e017445310.1371/journal.pone.0174453Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection.Ingrid CoutoMarilu VictoriaValdiléa G VelosoLorena RodriguesBeatriz GrinsztejnMarcus LacerdaFlamir VictoriaHugo PerazzoOBJECTIVE:The study aimed to evaluate the prevalence and predictor factors for compensated advanced chronic liver disease (c-ACLD) in patients with hepatitis Delta virus (HDV) infection. METHODS:This cross-sectional study included consecutive HDV-infected patients defined by positive anti-HDV. Patients with hepatitis C coinfection, liver transplantation or presence of conditions that limit liver (LSM) or spleen stiffness measurement (SSM) were excluded. Blood tests, abdominal ultrasound, SSM and LSM by transient elastography (FibroScan®) were performed at the same day. Alcohol consumption was quantified using the AUDIT score and c-ACLD was defined by LSM ≥ 15 kPa performed by an experimented operator blinded for clinical and laboratory data. RESULTS:101 patients were eligible and few patients were excluded due to negative anti-HDV (n = 7), hepatitis C coinfection (n = 2), liver transplantation (n = 10) and limitation for LSM or SSM (n = 5). Therefore, 77 patients [61% male, age = 43 (IQR,36-52) years] were included. The prevalence of c-ACLD was 57% (n = 44/77). Patients with c-ACLD had a higher rate of detectable HBV viral load (p = 0.039), higher levels of transaminases, GGT, alkaline phosphatases, total bilirubin and INR (p<0.001 for all), as well as lower platelet count and albumin levels (p>0.001 for both) compared to those without c-ACLD. Patients with c-ACLD had higher SSM [65.2 (IQR,33.8-75.0) vs 21.8 (16.5-32.0) kPa; p<0.001] and higher splenic volume [475 (IQR,311-746) vs 154 (112-283) cm3; p<0.001] compared to those without. Detectable HBV viral load (>10 UI/ml), alkaline phosphatase (per IU/L) and GGT levels (per IU/L) were independently associated with c-ACLD in all multivariate models. Splenic volume [per cm3,OR = 1.01 (95%CI,1.01-1.02);p = 0.002], SSM [per kPa, OR = 1.04 (1.01-1.07);p = 0.012] and splenomegaly [yes vs no,OR = 28.45 (4.42-182.95);p<0.001] were independently associated with c-ACLD. CONCLUSIONS:The prevalence of c-ACLD was high in patients with chronic HDV infection in western Amazon basin. HBV viral load, liver enzymes and splenic features can be used to predict severe liver disease in HDV-infected patients.http://europepmc.org/articles/PMC5362235?pdf=render |
| spellingShingle | Ingrid Couto Marilu Victoria Valdiléa G Veloso Lorena Rodrigues Beatriz Grinsztejn Marcus Lacerda Flamir Victoria Hugo Perazzo Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection. PLoS ONE |
| title | Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection. |
| title_full | Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection. |
| title_fullStr | Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection. |
| title_full_unstemmed | Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection. |
| title_short | Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection. |
| title_sort | prevalence and predictors for compensated advanced chronic liver disease c acld in patients with chronic hepatitis delta virus hdv infection |
| url | http://europepmc.org/articles/PMC5362235?pdf=render |
| work_keys_str_mv | AT ingridcouto prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection AT mariluvictoria prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection AT valdileagveloso prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection AT lorenarodrigues prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection AT beatrizgrinsztejn prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection AT marcuslacerda prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection AT flamirvictoria prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection AT hugoperazzo prevalenceandpredictorsforcompensatedadvancedchronicliverdiseasecacldinpatientswithchronichepatitisdeltavirushdvinfection |